Rankings
▼
Calendar
VRDN FY 2017 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
VRDN
Viridian Therapeutics, Inc.
$2B
FY 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$4M
+20.0% YoY
Gross Profit
-$16M
-390.2% margin
Operating Income
-$27M
-662.8% margin
Net Income
-$27M
-662.3% margin
EPS (Diluted)
$-20.66
Cash Flow
Operating Cash Flow
-$28M
Free Cash Flow
-$28M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$52M
Total Liabilities
$14M
Stockholders' Equity
$39M
Cash & Equivalents
$47M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4M
$3M
+20.0%
Gross Profit
-$16M
$789,000
-2079.7%
Operating Income
-$27M
-$13M
-112.1%
Net Income
-$27M
-$13M
-109.2%
← Q4 2016
All Quarters
Q1 2017 →